No abstract

Newer liposomal design exhibited promising potential to emerge as alternative anticancer therapeutics.

No abstract

Matrix metalloproteinases (MMPs) are a large group of calcium-dependent zinc containing endopeptidases which are mainly concerned with the remodeling of tissue along with degradation of the extracellular matrix. At the present scenario, there is knowledge of about 26 MMPs which are found to be highly regulated by the growth hormones, cytokines, etc., present within the body. At times of normal homeostasis, their levels within the body are low, and their number usually increases at times of pathological conditions. Its generation is known to occur from the pro-inflammatory cells and connective tissues. They may even lead to the process of apoptosis by its interactions with surface receptors. In the clinical trials sectors, various MMPs along with their inhibitors are examined to import the properties of being a high biomarker in the cancer diagnosis, antiangiogenic agents, various other disorders such as chronic allograft nephropathy, diabetic nephropathy, cardiovascular diseases, neuropathic pain, wound healing, angiogenesis processes, immune response, corneal ulceration, embryonic development, and nervous system disorders. As a result, enormous number of studies on this particular enzyme in the marking of cancer and their elevation in the above-mentioned diseases has to be carried out so that it would remain as a useful tool in their diagnosis. The present work is designed to emphasize the concise review of MMPs, in particularly MMP-2 and MMP-9 along with their variant roles, keeping in mind, that it would be advantageous for the researchers to bring out more promising results and to intensify diagnosis of various infirmities, especially in cancer.

In this work, polymeric nanoparticles containing Pregabalin was prepared and optimized the ideal concentration of polymer based on its in vitro release profile for a period of 24hrs.The nanoparticles were prepared by solvent displacement method using various concentrations of Eudragit S100 (EPNP1-EPNP5). The prepared nanoparticles were characterized for its particle size, zeta potential, drug content, entrapment efficiency and invitro drug release profile. The preformulation study results confirmed the compatibility between the drug and other excipients used in the formulation. The optimized formulation was selected based on its particle size, entrapment efficiency and in vitro drug release profile. The formulation which contains 300mg of Eudragit S100 (EPNP5) was selected as optimized concentration for the controlled release of Pregabalin for a period of 24hrs.